Eli Lilly and Pfizer Announce Joint R&D Initiative; $4.8 Billion Investment in Oncology
โข Pharmaceutical giants Eli Lilly and Pfizer announced a strategic research collaboration focusing on oncology and immunology, with combined commitments totaling $4.8 billion over five years to accelerate drug development and clinical trial timelines. โข The partnership will leverage Eli Lilly's metabolic disease expertise and Pfizer's vaccine platform capabilities to pursue combination therapies for hard-to-treat cancers, with initial clinical trials expected to commence in mid-2027. โข Industry analysts view the deal as emblematic of Big Pharma consolidating R&D resources amid rising drug development costs exceeding $2.6 billion per approved medication, while also signaling confidence in oncology market growth.
ft.com